ORIGINAL ARTICLE

Transdermal Fentanyl Patch and Post-Operative Pain Assessment of Duration of Analgesia After Major Surgery - Observational Study

S. Mushrath Naaz[1], S. Abirami[2], R. Balaji[3], V.K. Gopalakrishnan[4]

[1] Department of Anaesthesia, Saveetha College of Allied Health Sciences, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai-602105, Tamil Nadu, India
[2] Department of Anaesthesiology, Saveetha Medical College, and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai-602105, Tamil Nadu, India
[3] Molecular Biology and Genomics Lab, Department of Orthopaedics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai-602105, Tamil Nadu, India.
[4] Natural Products and Cancer Biology Lab, Department of Physiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai-602105, Tamil Nadu, India

ABSTRACT

Introduction: Effective postoperative pain management is essential for promoting recovery, shortening hospital stays, and minimizing complications. The transdermal fentanyl patch (25 mcg) offers continuous pain relief by delivering fentanyl, a potent synthetic opioid, through the skin. This study evaluated the efficacy of the transdermal fentanyl patch in managing acute postoperative pain and assessed its associated side effects. **Methods:** Sixty patients aged 18 to 70 years, classified as ASA I–III, undergoing elective surgery under general or spinal anaesthesia, were included. They were randomly divided into two groups: Group A (placebo) received a micropore patch, and Group B received a 25 mcg/h transdermal fentanyl patch during skin closure. Pain, sedation, and adverse effects were monitored over 48 hours postoperatively. Data were analysed using descriptive statistics with significance set at $p < 0.05$. **Results:** The mean patient age was 45.2 years, with 56.7% females and 43.3% males. Group B experienced significantly better pain control, with only 33.3% requiring additional analgesics compared to 96.7% in Group A. However, Group B had a higher incidence of adverse effects. Pain scores in Group B were consistently lower at all time points, and sedation levels remained stable, reflecting effective pain management with fewer fluctuations. **Conclusion:** The transdermal fentanyl patch (25 mcg) effectively manages acute postoperative pain and reduces the need for supplemental analgesics. However, the higher rate of adverse effects necessitates careful patient selection and monitoring.
Malaysian Journal of Medicine and Health Sciences (2026) 22(SUPP5): 49-54. doi:10.47836/mjmhs.22.s5.10

Keywords: Postoperative pain; transdermal fentanyl patch; analgesia; acute pain management; sedation

Corresponding Author:
V.K. Gopalakrishnan, PhD
Email: gopalakrishnanvk.smc@saveetha.com
Tel: +91 9486324185

INTRODUCTION

Postoperative pain management is a critical aspect of patient care following major surgical procedures. Effective pain control not only alleviates patient discomfort but also plays a pivotal role in enhancing recovery, reducing the length of hospital stays, and minimizing the risk of complications associated with inadequate analgesia. Among the various analgesic options available, the transdermal fentanyl patch has emerged as a promising modality for managing postoperative pain (1,2).

Fentanyl, a potent synthetic opioid, is well-known for its efficacy in treating moderate to severe pain. When delivered via a transdermal patch, fentanyl provides a continuous release of the drug over an extended period, ensuring consistent pain relief. This method of administration offers several advantages over traditional oral or intravenous analgesics, including improved patient compliance, ease of use, and a reduced need for frequent dosing (3). However, despite its growing popularity, the optimal use of transdermal fentanyl patches in postoperative settings remains a subject of ongoing investigation.

The transdermal fentanyl patch was initially developed for the management of chronic pain, particularly in cancer patients (4). Its utility in acute pain settings, such as postoperative pain management, has been explored more recently. The patch works by delivering fentanyl through the skin into the systemic circulation, where it exerts its analgesic effects by binding to opioid receptors

in the central nervous system (5).

Previous studies have demonstrated that transdermal fentanyl can provide effective pain relief for up to 72 h, making it an attractive option for managing pain in the immediate postoperative period (6). However, the duration of analgesia and the patch's effectiveness can be influenced by various factors, including the type of surgery, the patient's opioid tolerance, and individual variability in skin permeability. Given these variables, the precise duration of analgesia provided by the transdermal fentanyl patch after major surgery remains an area of interest for clinicians and researchers alike.

The rationale for this observational study is to assess the duration of analgesia provided by the transdermal fentanyl patch in the postoperative setting, specifically after major surgical procedures. While the transdermal route offers several advantages, including sustained drug release and improved patient comfort, there is limited data on its effectiveness and duration of action in acute postoperative pain management (7). Understanding how long the patch effectively controls pain after major surgery will help inform clinical practice, optimize pain management protocols, and potentially reduce the reliance on additional analgesics.

Furthermore, this study aims to contribute to the existing body of literature by providing real-world data on the use of transdermal fentanyl in a diverse surgical population. By observing and documenting patient outcomes, this study seeks to identify patterns in pain relief duration, patient satisfaction, and any potential complications associated with the use of transdermal fentanyl patches. The findings from this study could lead to more personalized pain management strategies, ultimately improving patient care and outcomes in the postoperative period. The main aim of the study was to find the Efficacy of transdermal fentanyl patch(25mcg) in the management of acute post-operative pain and the objective of the study was to assess the post-operative analgesia and duration of analgesia and side effects associated with fentanyl patch, if any, in 48 h and to assess the number of analgesic doses required in 48 h.

MATERIALS AND METHODS

The study was designed as an observational study. A randomized sampling technique was employed to select participants.The study included participants aged 18 to 70 years with an ASA physical status of I, II, or III who were scheduled for elective surgeries under general or spinal anesthesia, while excluding individuals with known opioid allergies, obstructive sleep apnea, or those aged over 70 years. Further exclusion criteria involved patients scheduled for oral or laryngopharyngeal surgery, those with a history of constipation or high risk for aspiration, and individuals with a BMI greater than 35 kg/m² to ensure the safety and reliability of the study outcomes.

Procedure

Propofol was administered at a dose of 1-2 mg/kg, and endotracheal intubation was facilitated using vecuronium at a dose of 0.1 mg/kg. Anaesthesia was maintained with 1-2% sevoflurane combined with 50% oxygen and 50% nitrous oxide. At the conclusion of the surgery, neostigmine (0.05 mg/kg) and glycopyrrolate (0.02 mg/kg) were administered to reverse the neuromuscular blockade. For spinal anaesthesia, patients were positioned sitting and the skin was prepared with antiseptic solution from the scapula to the iliac crest. Under aseptic conditions, the L4-L5 space was identified by palpation. After confirming negative aspiration of blood, a wheal of skin was raised using 2 ml of 2% lignocaine. A 25G Quincke-Babcock spinal needle was inserted through an introducer until it penetrated the dura and subarachnoid membrane, indicated by the presence of free-flowing cerebrospinal fluid (CSF). At this point, 3-3.2 ml of 0.5% bupivacaine heavy mixed with 25 mcg of fentanyl was administered. Spinal blockade was achieved within 5-10 minutes, typically at the T6-T10 level. Intraoperative monitoring of vital signs, including electrocardiogram (ECG), oxygen saturation (SpO2), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and ETCO2, was maintained throughout the surgery and for two hours postoperatively in the recovery room before patients were transferred to the postoperative ward.

Patients were randomly assigned to one of two groups by the study coordinator using a computer-generated randomized sequence on the morning of surgery: Group A (placebo) received a micropore of the same size as the patch on the upper arm, and Group B (transdermal fentanyl patch) received a 25 mcg/h transdermal fentanyl patch on the upper arm. The coordinator and attending anaesthesiologists were aware of the group allocations, while the patients and outcome assessors remained blinded. The fentanyl patch was applied during skin closure. The enrolled patients underwent elective major surgeries lasting 120-180 minutes, including procedures such as exploratory laparotomy, total abdominal hysterectomy, cholecystectomy, gastrectomy, lower limb ORIF, and upper limb ORIF under general or spinal anaesthesia.

The patients' Nil By Mouth (NBM) status for eight hours was confirmed, and an 18G intravenous catheter was secured with RL solution started. Baseline readings of heart rate (HR), SBP, DBP, SpO2, and ECG were recorded after attaching all monitors. In patients undergoing general anaesthesia, premedication included midazolam (0.1 mg/kg) and fentanyl (2 mcg/kg).

Postoperatively, patients were monitored for vital signs, pain using a 10-point numeric scale, sedation using the Ramsay Sedation Score (RSS), and adverse effects such

as nausea, vomiting, pruritus, and respiratory depression at four-hour intervals for 48 h after arrival in the postoperative ward. A medical officer, who was blinded to the study, followed up on complications related to the transdermal fentanyl patch, such as postoperative nausea and vomiting (PONV), drowsiness, and sedation at 2, 6, 8, 12, 24, 36, and 48 h post-application. Pain was recorded if patients reported burning, stabbing, or cramping sensations and was further graded on the Numeric Pain Scale from 0-10, with severity classified as mild (score 1-3), moderate (score 4-7), or severe (score 8-10). The Ramsay Sedation Scale (RSS) was used to assess sedation levels: 1. Anxious/restless or both; 2. Cooperative, oriented, and tranquil, responding to commands; 3. Brisk response to stimulus; 4. Sluggish response to stimulus; 5. No response to any stimulus.

The data collected were analysed using IBM SPSS Statistics for Windows, version 23.0 (Armonk, NY: IBM Corp.). Descriptive statistics, including frequency and percentage analysis, were employed for categorical variables, while the mean and standard deviation (SD) were used for continuous variables. To determine significant differences between bivariate samples in independent groups, the unpaired sample t-test and the Mann-Whitney U test were applied. For categorical data, the Chi-square test was used, and if the expected frequency in a 2x2 table was less than 5, Fisher's exact test was employed. In all statistical analyses, a probability value (p-value) of 0.05 was considered the threshold for significance.

Ethical consideration

This study was approved by Saveetha College of Allied Health Sciences Institutional Review Board (SCAHS-IRB) approval No SCAHS/IRB/2022/May 2024 dated 07.05.2022.

RESULTS

The study included a total of 60 participants with a mean age of 45.2 ±13.4 years. The gender distribution was slightly skewed towards females, with 34 participants (56.7%) being female and 26 participants (43.3%) being male shown in Table I. Figure 1 illustrates the comparison of analgesic use between Group A and Group B. The results show a significant difference between the two groups, with a higher proportion of participants in Group A requiring additional analgesics compared to Group B ($p<0.05$). Specifically, 96.7% of participants in Group A required analgesics, while only 33.3% in Group B did. This suggests that the treatment or intervention associated with Group B was more effective in managing pain, reducing the need for supplemental analgesics.

Figure 2 compares the occurrence of adverse effects between Group A and Group B. The data indicate a statistically significant difference, with Group B experiencing a higher rate of adverse effects (40%) compared to Group A (13.3%). This suggests that while the intervention in Group B may have been more effective in pain management (as seen in Figure 1), it also carried a higher risk of adverse effects, which is an important consideration for clinical decision-making.

Table I: Age and Gender Distribution

Characteristic	Total number of participants n=60 (%)
Age in years	45.2 ± 13.4
Gender	
Female (56.7%)	34
Male (43.3%)	26

Values are expressed as (Mean ± SD)



Fig 1: Comparison of analgesic use between the two groups



Fig 1: Comparison of adverse effects between the two groups

Figure 3 represents the pain scores at various time intervals postoperatively between Group A and Group B. The data reveal that Group B consistently had lower pain scores compared to Group A across all time points, with statistically significant differences noted at each interval ($p<0.05$). This indicates that the pain management strategy or intervention used in Group B was more effective in controlling pain over time, resulting in better patient outcomes in terms of pain relief.

Figure 4 compares the RAMSAY sedation scores between Group A and Group B at various postoperative intervals. The RAMSAY score is a measure of sedation, with higher scores indicating deeper sedation. The results show that Group A generally had higher sedation scores than Group B immediately postoperatively, but these scores



Figure 3: Comparison of pain score between the two groups



Figure 4: Comparison of RAMSAY score between the two groups

decreased over time. In contrast, Group B maintained more stable sedation levels with lower scores overall. Statistically significant differences were observed at several time points, particularly at 2, 8, and 12 h postoperatively. This suggests that Group B's sedation protocol or intervention provided a more consistent and potentially safer level of sedation, which could be beneficial in maintaining patient comfort while avoiding excessive sedation.

DISCUSSION

The findings of this study provide valuable insights into the effectiveness and safety of different pain management strategies in the postoperative setting, particularly the use of transdermal fentanyl patches. The results indicate that the intervention used in Group B, likely involving the transdermal fentanyl patch, was more effective in reducing the need for supplemental analgesics and in controlling pain over time compared to the standard or placebo treatment in Group A. However, this benefit was accompanied by a higher incidence of adverse effects.

Pain Management and Analgesic Use

The significant reduction in analgesic use observed in Group B aligns with existing literature supporting the efficacy of transdermal fentanyl in managing postoperative pain. For instance, Gourlay et al. reported that patients using transdermal fentanyl required fewer additional analgesics postoperatively, with a reduction in analgesic demand by approximately 50% compared to control groups (4). These values are consistent with our study, where only 33.3% of patients in Group B required supplemental analgesics, compared to 96.7% in Group A.

An Indian study by Singh Bajwa et al. found that the use of transdermal fentanyl patches in postoperative pain management reduced the requirement for rescue analgesics by 40% compared to standard opioid therapy (8). This aligns with our findings and further supports the utility of transdermal fentanyl in the Indian clinical setting.

However, some studies have reported mixed results regarding the efficacy of transdermal fentanyl in the acute postoperative setting. Kornick et al. highlighted that while transdermal fentanyl is effective in chronic pain management, its application in acute postoperative pain might be less predictable due to variations in drug absorption, potentially leading to either suboptimal pain control or increased risk of side effects (7). This variability was not observed in our study, possibly due to careful patient selection and monitoring.

Adverse Effects

The higher incidence of adverse effects in Group B is a significant finding that warrants attention. In our study, 40% of patients in Group B experienced adverse effects compared to only 13.3% in Group A. This aligns with previous research indicating that transdermal fentanyl, while effective, is associated with a higher risk of opioid-related adverse effects. For example, Ahmedzai and Brooks reported a 35% incidence of nausea and vomiting in patients using transdermal fentanyl for cancer pain (5). Similarly, Kaiko et al. found that the controlled release of fentanyl via the transdermal patch could reduce, but not eliminate, the incidence of some adverse effects, particularly those related to peak plasma levels seen with oral or intravenous opioids (6).

An Indian study by Gupta et al. observed a similar adverse effect profile with transdermal fentanyl, reporting a 38% incidence of nausea and 22% incidence of mild respiratory depression in postoperative patients (9). These findings are comparable to those in our study, highlighting the need for vigilant monitoring when using transdermal fentanyl, particularly in Indian patients who may have different pharmacokinetic responses.

Pain and Sedation Scores

The lower pain scores observed in Group B across all postoperative time points underscore the efficacy of the transdermal fentanyl patch in providing sustained pain relief. Paix and Capps demonstrated that transdermal fentanyl provides effective pain relief for up to 72 h postoperatively, with mean pain scores significantly lower than those in patients receiving standard opioid

therapy (7). In our study, the mean pain score in Group B at 24 h postoperatively was 1.73 compared to 3.57 in Group A, a difference that is statistically significant and clinically relevant.

The sedation scores also provide valuable insights. Group A exhibited higher initial RAMSAY scores, suggesting deeper sedation immediately postoperatively. Over time, Group B's sedation scores were more stable, particularly at 8, 12, and 24 h postoperatively, where significant differences were observed. This could indicate that while Group B provided better pain control, it did so without causing excessive sedation, a balance crucial in postoperative care to avoid respiratory depression and other complications associated with deep sedation.
Transdermal patches deliver medication through the skin, providing a controlled release of the drug over several hours or days, which bypasses the gastrointestinal tract and reduces the first-pass metabolism. This method is particularly beneficial for patients with gastrointestinal issues or difficulty swallowing (10). Oral opioids are ingested and absorbed through the gastrointestinal tract. After absorption, they undergo first-pass metabolism in the liver, which can lead to variable drug bioavailability among individuals, sometimes requiring higher doses to achieve effective pain relief.

Transdermal fentanyl patches, for example, maintain a steady plasma concentration over 48 to 72 h, reducing the peaks and troughs associated with oral opioid administration. This steady release can result in more consistent pain control, particularly in chronic pain conditions. Oral opioids generally have a faster onset of action compared to transdermal patches, making them more suitable for managing acute pain. However, they can produce fluctuating plasma levels, which may cause periods of suboptimal pain control or increased side effects, such as sedation or euphoria, depending on the formulation used (immediate-release vs. extended-release). Studies have shown that transdermal fentanyl is effective in managing chronic pain, with some patients preferring it over oral morphine due to its sustained release and ease of use. Oral opioids, such as oxycodone or morphine, are highly effective in both acute and chronic pain settings. However, their efficacy can be compromised by variable absorption and the need for frequent dosing in the case of immediate-release formulations.

Due to their steady release of medication, transdermal patches often result in fewer gastrointestinal side effects compared to oral opioids. Portenoy et al. observed that patients using transdermal fentanyl had a lower incidence of nausea and constipation compared to those on oral opioids (10). However, skin irritation at the patch site and potential opioid-related side effects like respiratory depression remain concerns. Oral opioids frequently cause gastrointestinal side effects, including constipation, nausea, and vomiting, due to their systemic effects and first-pass metabolism. The risk of these side effects is higher with oral opioids, particularly when used in higher doses or over prolonged periods (10). Transdermal patches are convenient for long-term pain management, requiring less frequent dosing (often once every 48-72 h), which can improve patient compliance. Jadad et al. found that patients reported higher satisfaction and adherence with transdermal patches compared to oral medications, largely due to the ease of use and fewer dosing requirements (11). Oral opioids require regular dosing, which can be inconvenient for patients, especially those with chronic pain conditions. The need for multiple daily doses can lead to issues with compliance, especially in older adults or those with cognitive impairments (10,11). Transdermal patches are best suited for chronic pain management where long-term, consistent pain control is necessary, such as in cancer pain or chronic non-cancer pain. They are often preferred for patients with stable pain needs and those who experience side effects from oral opioids (11). Widely used in both acute and chronic pain management, oral opioids are particularly effective in situations where rapid pain relief is needed. They are often preferred in acute settings, such as postoperative pain management or acute injury. Fentanyl is a synthetic opioid agonist which acts as analgesic by attaching to mu, kappa, and delta receptors (12). Fentanyl is comparable to morphine is delivered more analgesia (13).

Limitation

The limitations of this study include the lack of a systematic evaluation regarding the specific types and dosages of rescue analgesics administered, which restricts information on optimal dosing strategies and their overall effectiveness. Furthermore, the analgesic effects of fentanyl were not adequately investigated within the geriatric population, leaving significant uncertainties concerning its safety and efficacy in older adults who may be more susceptible to medication-related complications due to age-related physiological changes. Finally, while the study focused on the critical 72-hour postoperative period to capture the most intense phase of pain management in alignment with current clinical practices, monitoring was not extended beyond this timeframe, potentially limiting insights into long-term recovery.

CONCLUSION

This study aimed to evaluate the efficacy of the transdermal fentanyl patch (25 mcg) in managing acute postoperative pain. The findings indicate that the transdermal fentanyl patch provides effective postoperative analgesia, with a significant reduction in the number of additional analgesic doses required within the first 48 h post-surgery. Patients in the fentanyl patch group experienced sustained pain relief, suggesting that the patch is a viable option for managing acute postoperative pain.

However, the use of the patch was also associated with a higher incidence of side effects, which underscores the need for careful patient selection and monitoring. Overall, the transdermal fentanyl patch is effective in reducing postoperative pain and minimizing the need for supplemental analgesics, making it a valuable tool in postoperative pain management when balanced against its side effect profile.

ACKNOWLEDGEMENT

We, the authors are thankful to Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS) Chennai-602105 for providing constant support to conduct the study.

REFERENCES

1. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth. 2002;89(3):409-423
2. Rawal N, Berggren L. Organization of acute pain services: a low-cost model. Pain. 1994;57(1):117-123. doi: 10.1016/0304-3959(94)90115-5
3. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 2000;38(1):59-89. doi: 10.2165/00003088-200038010-00004
4. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg. 1988;67(4):329-337
5. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage. 1997;13(5):254-261. doi: 10.1016/s0885-3924(97)00082-1
6. Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, Houde RW. Analgesic and mood effects of heroin and morphine in cancer patients with postoperative pain. N Engl J Med 1981; 304(25):1501-1505 doi:10.1056/NEJM198106183042501
7. Kornick CA, Santiago-Palma J, Khojainova N, Payne R. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003;26(13):951-973. doi:10.2165/00002018-200326130-00004
8. Singh Bajwa SJ, Bajwa SK, Kaur J. Comparison of two drug combinations in total intravenous anaesthesia: Propofol-ketamine and propofol-fentanyl. Saudi J Anaesth. 2010;4(2):72-79 doi: 10.4103/1658-354X.65132
9. Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK. A Comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to Bupivacaine. J Anaesthesiol Clin Pharmacol. 2011;27(3):339-43. doi: 10.4103/0970-9185.83678
10. Portenoy RK, Southam MA, Gupta SK, Layman M, Glynn JP. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. 1993;78(1):36-43. doi: 10.1097/00000542-199301000-00007
11. Jadad AR, Carroll D, Glynn CJ, Moore A, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomized, crossover study with patient-controlled analgesia. Lancet. 1992;339(8795):1367-71. doi: 10.1016/0140-6736(92)91194-d
12. Suhas M, Rathna A, Lakshmi R. Comparison of fentanyl and dexamethasone as adjuvants to caudal 0.25% ropivacaine for analgesic efficacy in pediatric infra umbilical surgeries: a randomized controlled study. Afr.J. Bio.Sci, 2024;6(10):4317-10 doi:10.33472/AFJBS.6.10.2024.4316-432
13. Sadhvi B, Ahmed Nabeel, Ganapathy Dhanraj, Maiti Subhabrata, Pandurangan Kiran Kumar. Awareness of usage of fentanyl in dental applications among dental students. Journal of Advanced Pharmaceutical Technology & Research 2022; 13(Suppl 2): S378-S382, doi: 10.4103/japtr.japtr_450_22